Observational studyYonsei medical journal2025
Drug-Coated Balloon-Based Intervention for De Novo Acute Myocardial Infarction.
Observational study in Yonsei medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04619277 (Impact of Drug-coated Balloon Treatment in de Novo Coronary Lesion), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Drug-coated Balloon Treatment in de Novo Coronary Lesion
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeData on drug-coated balloon (DCB) treatment in acute myocardial infarction (AMI) are limited. We aimed to assess the efficacy and safety of DCB revascularization in percutaneous coronary intervention (PCI) in patients with de novo AMI. MATERIALS AND
methodsThree hundred twenty-nine patients with de novo AMI who were successfully treated with DCB-based PCI were retrospectively enrolled. Patients treated with DCB-based PCI were compared to propensity score-matched patients who underwent conventional PCI with second-generation drug-eluting stent (DES), using data from a DES registry. Both groups were followed over 2 years to assess net adverse cardiovascular events (NACE).
resultsThe cumulative incidences of NACE [6.2% vs. 10.8%; hazard ratio (HR) (95% confidence interval, CI): 0.54 (0.33-0.88);
conclusionIn patients with de novo AMI, DCB-based PCI showed more favorable clinical outcomes after 2 years of follow-up compared to conventional DES-only PCI. DCB-based PCI may serve as a safe and effective alternative to DES-only PCI in carefully selected patients with satisfactory pre-dilation results (Impact of Drug-Coated Balloon Treatment in De Novo Coronary Lesion; NCT04619277).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.